172 related articles for article (PubMed ID: 20809870)
1. Asimadoline in the treatment of irritable bowel syndrome.
Mangel AW; Williams VS
Expert Opin Investig Drugs; 2010 Oct; 19(10):1257-64. PubMed ID: 20809870
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
[TBL] [Abstract][Full Text] [Related]
3. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.
Camilleri M
Neurogastroenterol Motil; 2008 Sep; 20(9):971-9. PubMed ID: 18715494
[TBL] [Abstract][Full Text] [Related]
4. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.
Delvaux M; Beck A; Jacob J; Bouzamondo H; Weber FT; Frexinos J
Aliment Pharmacol Ther; 2004 Jul; 20(2):237-46. PubMed ID: 15233705
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome.
Szarka LA; Camilleri M; Burton D; Fox JC; McKinzie S; Stanislav T; Simonson J; Sullivan N; Zinsmeister AR
Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1268-75. PubMed ID: 17900994
[TBL] [Abstract][Full Text] [Related]
6. The safety of novel drugs used to treat irritable bowel syndrome.
Mozaffari S; Nikfar S; Abdollahi M
Expert Opin Drug Saf; 2014 May; 13(5):625-38. PubMed ID: 24669839
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
8. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
9. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
Camilleri M
Expert Opin Pharmacother; 2013 Jun; 14(9):1151-60. PubMed ID: 23621801
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F; Lembo A
Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
[TBL] [Abstract][Full Text] [Related]
11. Investigational agents for the irritable bowel syndrome.
Ghaith O; El-Halabi M; Hashash JG; Sharara AI
Expert Opin Investig Drugs; 2010 Oct; 19(10):1161-78. PubMed ID: 20836617
[TBL] [Abstract][Full Text] [Related]
12. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.
Mangel AW; Fehnel SE
Neurogastroenterol Motil; 2008 Oct; 20(10):1086-93. PubMed ID: 18826559
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis.
Li X; Li B; Zhang J; Chen T; Wu H; Shi X; Ma J; Qin J; Tang X; Wang F
Medicine (Baltimore); 2021 Jan; 100(4):e24361. PubMed ID: 33530231
[TBL] [Abstract][Full Text] [Related]
14. Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.
Mangel AW; Hicks GA
Clin Exp Gastroenterol; 2012; 5():1-10. PubMed ID: 22346361
[TBL] [Abstract][Full Text] [Related]
15. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.
Talley NJ; Choung RS; Camilleri M; Dierkhising RA; Zinsmeister AR
Aliment Pharmacol Ther; 2008 Jun; 27(11):1122-31. PubMed ID: 18331462
[TBL] [Abstract][Full Text] [Related]
16. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
[TBL] [Abstract][Full Text] [Related]
17. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
[TBL] [Abstract][Full Text] [Related]
19. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S
Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
